ZGNX News and Press, Zogenix Inc. From 08/26/19

Advances Zogenix’s strategy to provide transformative therapies to patients and families living with serious rare diseases Adds MT1621, a proprietary, late-stage investigational medicine targeting Thymidine Kinase 2 deficiency (TK2d) that has received FDA Breakthrough Thera...

Zogenix, Inc. (ZGNX) Q2 2019 Earnings Conference Call August 6, 2019 4:30 AM ET Company Participants Brian Ritchie – LifeSci Advisors Stephen Farr – Chief Executive Officer Michael Smith – Chief Financial Officer Ashish Sagrolikar – Chief Commercial ...

Zogenix (NASDAQ: ZGNX ): Q2 GAAP EPS of -$0.89 misses by $0.11 . More news on: Zogenix, Inc., Earnings news and commentary, Healthcare stocks news, Read more ...

Agreement reached with U.S. FDA for resubmission of NDA for FINTEPLA® for the treatment of Dravet syndrome; resubmission expected in September Enrollment complete for FINTEPLA global Phase 3 trial in Lennox Gastaut syndrome; top-line data anticipated in Q1 2020 Strengthene...

Zogenix (NASDAQ: ZGNX ) is scheduled to announce Q2 earnings results on Tuesday, August 6th, after market close. The consensus EPS Estimate is -$0.77 (+6.1% Y/Y) and the consensus Revenue Estimate is $4.11M Over the last 2 years, zgnx has beaten EPS estimates 38% of the time and has ...

EMERYVILLE, Calif., July 30, 2019 (GLOBE NEWSWIRE) -- Zogenix, Inc. (NASDAQ: ZGNX), a global pharmaceutical company developing rare disease therapies, today announced that it will report its financial results for the three and six months ended June 30, 2019, after the market close, and will...

EMERYVILLE, Calif., July 08, 2019 (GLOBE NEWSWIRE) -- Zogenix, Inc. (NASDAQ: ZGNX), a global pharmaceutical company developing rare disease therapies, today announced that it has completed enrollment for, and randomized the last patient into the treatment period of, Study 1601, the Company&...

Zogenix ( ZGNX ) had a great day last week, because the FDA had agreed to allow it to resubmit its New Drug Application ((NDA)) for Fintepla for the treatment of seizures associated with Dravet syndrome. This is a major turn of events, especially since many months ago, the stock was crus...

Gainers:  Cemtrex (NASDAQ: CETX ) +120% . The Howard Hughes (NYSE: HHC ) +38% . J.Jill (NYSE: JILL ) +21% . Foresight Autonomous Holdings (NASDAQ: FRSX ) +21% . Zogenix (NASDAQ: ZGNX ) +21% . Herman Miller (NASDAQ: MLHR ) +18% . Atossa Genetics (NASDAQ: ATOS ) +16% .  Dova...

Dova Pharmaceuticals (NASDAQ: DOVA ) +32%  as FDA OKs Dova's Doptelet for low blood platelets in ITP patients. More news on: Dova Pharmaceuticals, Inc., Atossa Genetics Inc., Zogenix, Inc., Stocks on the move, Read more ...